Scientist / Senior Scientist, Preclinical Formulation

Nurix, Inc.
San Francisco, CA
Mar 08, 2018
Required Education
Position Type
Full time

Join us in the most challenging and rewarding science of our lives.

We are seeking a seasoned Preclinical formulator who will be responsible for preformulation characterization of preclinical compounds.

You will prepare dose formulation for PK/PD/Tox studies as needed and transition lead compounds to clinical formulations. You will develop immediate/modified release oral and/or parenteral dosage forms, oversee contract manufacturing organizations (CMOs) for formulation development, scale up and GMP manufacturing activities. As such you will need to have a strong ability to troubleshoot problems.

In addition, you will serve as formulation lead in multidisciplinary project teams and/or sub-teams, evaluate new formulation and preformulation technologies, have an expert understanding of preformulation and formulation areas and use published literature to extend understanding as well as consult internal and external experts as needed, and prepare and/or review written documents including technical reports, batch records, regulatory filings.

You must be self-driven, resourceful, organized and focused, and enjoy being a part of a dynamic team in a project-based environment solving challenging scientific problems to benefit patients.


  • Ph.D. with at least 2-5 years of experience or MS/BS candidates with at least 7-10 years of experience in small molecule formulation development in the pharmaceutical industry
  • Experience with CMO/CRO oversight is required
  • Highly independent, self-motivated and integrate well within a team
  • Excellent communication and written skills 
  • Good organizational skills with an ability to work in a high paced team environment to meet deadlines and prioritize work on multiple projects 

Nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating E3 ubiquitin ligases within the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. Nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the UPS, enabling the development of novel therapeutics that can restore normal cellular homeostasis.

Nurix was founded by internationally recognized experts in the UPS field and received its initial funding from leading life science investors, Third Rock Ventures and The Column Group.  In 2015, Nurix entered into a multi-year strategic collaboration with Celgene to discover and develop next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology.

Nurix is based in San Francisco’s biotechnology hub, Mission Bay – where academia and industry come together for cutting-edge life-saving research.